Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) reported on Wednesday the availability of Atomoxetine Capsules, USP in the US market.
In addition, the company's Atomoxetine Capsules, USP is available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg with 30 counts bottle size. Atomoxetine is used to treat attention-deficit hyperactivity disorder (ADHD), including psychological, social, and other treatments. It may help to increase the ability to pay attention, concentrate, stay focused and stop fidgeting.
The company said the US Food and Drug Administration (USFDA) approved Atomoxetine Capsules, USP, is the therapeutic equivalent generic version of Strattera (atomoxetine) Capsules. Straterra is a registered trademark of Eli Lilly and Company.
For the most recent 12 months ending in August 2018, the Strattera brand and generic had US sales of about USD304m MAT, according to IMS Health.
Amneal Pharmaceuticals appoints David A. Buchen as SVP, chief legal officer and corporate secretary
Ironwood Pharmaceuticals and Allergan reach agreement to resolve Mylan LINZESS patent litigation
Teva and Amgen Resolve Ongoing Dispute Over Teva's Generic Cinacalet HCl Product
Ironwood, Allergan Agree Settlement with Mylan Resolving Linzess Patent Litigation
Teva announces resolution of litigation with Amgen over Teva's generic cinacalet HCl product
Innovent's phase III clinical trial of anti-PD-1 antibody Tyvyt reports first patient dosing
Dr. Reddy's Laboratories Launches Sevelamer Carbonate for Oral Suspension in the US Market